Drug Shortage Report for ERWINASE
Report ID | 2952 |
Drug Identification Number | 02237815 |
Brand name | ERWINASE |
Common or Proper name | Erwinia L-asparaginase |
Company Name | JAZZ PHARMACEUTICALS FRANCE SAS |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | ASPARAGINASE |
Strength(s) | 10000UNIT |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS |
Packaging size | 3 mL vials |
ATC code | L01XX |
ATC description | OTHER ANTINEOPLASTIC AGENTS |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | 2017-03-14 |
Actual start date | |
Estimated end date | 2017-06-30 |
Actual end date | 2017-06-30 |
Shortage status | Resolved |
Updated date | 2018-03-07 |
Company comments | Reason for ongoing shortage in Canada (less than 3-months supply) due to global capacity constraints in manufacturing leading to just-in time supply with intermittent shortages. Additionally demand has increased from average of 51 packs per month to 105 packs per month. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 84 QUAI CHARLES DE GAULLE CITY ONE LYON, AUVERGNE-RHONE-ALPES FRANCE 69006 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2018-03-07 | English | Compare |
v7 | 2017-04-24 | French | Compare |
v6 | 2017-04-24 | English | Compare |
v5 | 2017-03-16 | French | Compare |
v4 | 2017-03-16 | English | Compare |
v3 | 2017-03-16 | English | Compare |
v2 | 2017-03-15 | French | Compare |
v1 | 2017-03-15 | English | Compare |
Showing 1 to 8 of 8